tallózása szerző szerint "Hajek R"

A találatok rendezése: Rendezés: Találatok:

  • Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. 
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi, Tamás; Spicka I; Oriol A; Hajek R; Rosinol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A; the ASPIRE Investigators (2014)
    Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase ...
  • Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment 
    Dimopoulos MA; Stewart AK; Masszi, Tamás; Spicka I; Oriol A; Hajek R; Rosinol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A (2017)
    Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomi ...
  • Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma 
    Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi, Tamás; Spencer A; Hajek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG (2017)
    The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma ...